543245 Stock Overview
Engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 543245 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Gland Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,449.10 |
| 52 Week High | ₹2,220.95 |
| 52 Week Low | ₹1,413.75 |
| Beta | 0.28 |
| 1 Month Change | -18.79% |
| 3 Month Change | -15.01% |
| 1 Year Change | -26.86% |
| 3 Year Change | -57.61% |
| 5 Year Change | n/a |
| Change since IPO | -20.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543245 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.8% | 1.1% | -0.4% |
| 1Y | -26.9% | 17.1% | 6.3% |
Return vs Industry: 543245 underperformed the Indian Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: 543245 underperformed the Indian Market which returned 6.3% over the past year.
Price Volatility
| 543245 volatility | |
|---|---|
| 543245 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 543245 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 543245's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 4,208 | Shyamakant Giri | www.glandpharma.com |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services.
Gland Pharma Limited Fundamentals Summary
| 543245 fundamental statistics | |
|---|---|
| Market cap | ₹243.48b |
| Earnings (TTM) | ₹7.04b |
| Revenue (TTM) | ₹57.29b |
34.0x
P/E Ratio4.2x
P/S RatioIs 543245 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543245 income statement (TTM) | |
|---|---|
| Revenue | ₹57.29b |
| Cost of Revenue | ₹25.57b |
| Gross Profit | ₹31.72b |
| Other Expenses | ₹24.68b |
| Earnings | ₹7.04b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 20, 2025
| Earnings per share (EPS) | 42.76 |
| Gross Margin | 55.37% |
| Net Profit Margin | 12.30% |
| Debt/Equity Ratio | 3.7% |
How did 543245 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 16:10 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gland Pharma Limited is covered by 22 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Neha Manpuria | BofA Global Research |